AMSBIO is a global supplier of research products and custom services for biological and pharmaceutical research.
Founded in 1987, AMS Biotechnology (AMSBIO) has established itself as a prominent player in the acceleration of discovery within the medical, nutrition, cosmetics, and energy industries. The company's comprehensive range encompasses specialist antibodies, peptides, recombinant proteins, and in-depth expertise in extracellular matrices. AMSBIO's proficiency in cell culture allows tailored cell systems to optimize screening outcomes and prognosis, while their molecular detection reagents and Biorepository offer tissue DNA, RNA, protein, and microarray products. Key research areas include oncology, regenerative medicine, environmental analysis, cytotoxicity screening, glycomics, and stem cell biology. With headquarters in the United Kingdom, AMSBIO's contributions span diverse sectors, making it a key player in the biotechnology and healthcare industries.
There is no investment information
No recent news or press coverage available for AMSBIO.